VEXOL
LOE Approachingrimexolone
NDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEXOL (rimexolone) is a corticosteroid ophthalmic suspension approved in 1994 for inflammatory conditions of the eye. It is administered topically as drops and works through glucocorticoid receptor agonism to suppress ocular inflammation. The drug is indicated for post-operative inflammation and allergic conjunctivitis.
LOE Approaching
As LOE approaches, the brand team is likely contracting; career opportunities focus on defending market share against generics rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VEXOL offers limited career growth due to its LOE-approaching status and negligible linked job openings. Roles are primarily defensive—protecting existing market share against generics—rather than developmental or innovative.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.